Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPA1 | O60313 | 1/20 | 0.63 |
| ▸ | EIF5B | O60841 | 1/20 | 0.63 |
| ▸ | MET | P08581 | 1/20 | 0.63 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395775 | 1.00 | OPA1 (0.63) | OPA1EIF5BMETHMOX2KDM4E | |
| SCHEMBL5299701 | 0.90 | OPA1 (0.61) | OPA1EIF5BMETHMOX2MAPT | |
| SCHEMBL1395846 | 0.90 | OPA1 (0.61) | OPA1EIF5BMETHMOX2MAPT | |
| SCHEMBL1395847 | 0.88 | OPA1 (0.61) | OPA1EIF5BMETHMOX2HTR2A | |
| SCHEMBL1395820 | 0.87 | OPA1 (0.60) | OPA1EIF5BMETHMOX2KDM4E | |
| SCHEMBL1395828 | 0.87 | OPA1 (0.73) | OPA1EIF5BMETHMOX2KDM4E | |
| SCHEMBL5307336 | 0.86 | OPA1 (0.66) | OPA1EIF5BMETHMOX2KDM4E | |
| SCHEMBL1395726 | 0.86 | OPA1 (0.66) | OPA1EIF5BMETHMOX2HTR2A | |
| SCHEMBL1395821 | 0.86 | OPA1 (0.66) | OPA1EIF5BMETHMOX2KDM4E | |
| SCHEMBL1395827 | 0.86 | OPA1 (0.66) | OPA1EIF5BMETHMOX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. | 2014-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | OPA1 88/4885EIF5B 402/4885MET 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.